Treatment of Presbyopia in Emmetropic Patients With Multifocal Excimer Laser Ablation: Long Follow-up

Sunday, April 19, 2015: 8:21 AM
Room 1A (San Diego Convention Center)
María José Cosentino, MD
Daniel A. Badoza, MD
Melisa M. Moreno, MD

To analyze the efficacy and safety in the refractive results after treating presbyopia in emmetropic patients using multifocal platform.

We studied prospectively 50 emmetropic eyes, between 45 and 55 years old.  We performed in non-dominant eye LASIK technique using SupraCOR multifocal excimer laser platform (Bausch + Lomb). We measured stability, efficacy, predictability, and safety at preoperative and postoperative 12, 24, and 36 months.

Preoperative spherical equivalent was 0.39 ± 0.57 D; preoperative far uncorrected visual acuity (fUCVA) was 0.64 ± 0.27 and far best spectacle corrected visual acuity (fBSCVA) was 0.94 ± 0.09; near uncorrected visual acuity (nUCVA) was J5 in 100% of cases.At 24 months, spherical equivalent was -0.16 ± 0.37 D; fUCVA was 0.77 ± 0.19;  fBSCVA 0.90 ± 0.14; nUCVA was 0.83 ± 0.27.

To treat emmetropic presbyopes patients in the non-dominant eye is stable and safe when appropriate inclusion criteria are met.